BOLERO: An international phase III trial program for the treatment of HER2/neo-positive (BOLERO 1/3) and ER-positive (BOLERO 2) metastatic breast cancer with the mTOR inhibitor RAD001 (Everolimus)

被引：0
|
作者：
Jonat, W. [5 ]
Eiermann, W. [1 ]
Janni, W. [2 ]
Rody, A. [3 ]
Muth, M. [4 ]
机构：
[1] Frauenklin vom Roten Kreuz, Munich, Germany
[2] Univ Frauenklin, Dusseldorf, Germany
[3] Univ Frauenklin, Frankfurt, Germany
[4] Novartis Pharma GmbH, BU Onkol, Nurnberg, Germany
[5] Univ Frauenklin, Kiel, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] BOLERO-3: Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer
    Toi, M.
    Masuda, N.
    Andre, F.
    Ishiguro, H.
    Fasolo, A.
    Xu, B.
    Jerusalem, G.
    Shen, K.
    Wilks, S.
    O'Regan, R.
    Isaacs, C.
    Zhang, Y.
    Taran, T.
    Yap, Y-S
    CANCER RESEARCH, 2013, 73
  • [2] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [3] Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2-metastatic breast cancer treated with everolimus (mTOR inhibitor).
    Ali, Suhail M.
    Reising, Albert
    Leitzel, Kim
    Drabick, Joseph J.
    Truica, Cristina I.
    Vasekar, Monali K.
    Menon, Harry
    Nagabhairu, Vinod
    Polimera, Hyma Vani
    Pancholy, Neha
    Moku, Prashanth Reddy
    Maddukuri, Ashok
    Schmid, Herbert
    He, Wei
    Millholland, John
    Lavin, Meredith
    Hofsess, Scott J.
    Sweetman, Robert William
    Hortobagyi, Gabriel N.
    Lipton, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    CANCER RESEARCH, 2016, 76
  • [5] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer (MBC)
    Mayer, I. A.
    Means-Powell, J.
    Abramson, V. G.
    Shyr, Y.
    Balko, J. M.
    Kuba, M. G.
    Gharavii, H. M.
    Schlabach, L.
    Arteaga, C. L.
    Pietenpol, J. A.
    CANCER RESEARCH, 2011, 71
  • [7] Breast Cancer Management with Melanie E Royce: BOLERO-4 Phase II trial of first-line everolimus plus letrozole in ER+, HER2(-) advanced breast cancer
    Royce, Melanie E.
    Wijayatunga, Roshaine
    BREAST CANCER MANAGEMENT, 2016, 5 (03) : 89 - 92
  • [8] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
    Andre, Fabrice
    O'Regan, Ruth
    Ozguroglu, Mustafa
    Toi, Masakazu
    Xu, Binghe
    Jerusalem, Guy
    Masuda, Norikazu
    Wilks, Sharon
    Arena, Francis
    Isaacs, Claudine
    Yap, Yoon-Sim
    Papai, Zsuzsanna
    Lang, Istvan
    Armstrong, Anne
    Lerzo, Guillermo
    White, Michelle
    Shen, Kunwei
    Litton, Jennifer
    Chen, David
    Zhang, Yufen
    Ali, Shyanne
    Taran, Tetiana
    Gianni, Luca
    LANCET ONCOLOGY, 2014, 15 (06): : 580 - 591
  • [9] Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
    Hurvitz, Sara A.
    Andre, Fabrice
    Jiang, Zefei
    Shao, Zhimin
    Mano, Max S.
    Neciosup, Silvia P.
    Tseng, Ling-Min
    Zhang, Qingyuan
    Shen, Kunwei
    Liu, Donggeng
    Dreosti, Lydia M.
    Burris, Howard A.
    Toi, Masakazu
    Buyse, Marc E.
    Cabaribere, David
    Lindsay, Mary-Ann
    Rao, Shantha
    Pacaud, Lida Bubuteishvili
    Taran, Tetiana
    Slamon, Dennis
    LANCET ONCOLOGY, 2015, 16 (07): : 816 - 829
  • [10] Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial
    Baselga, J.
    Campone, M.
    Piccart-Gebhart, M. J.
    Burris, H. A.
    Rugo, H. S.
    Noguchi, S.
    Gnant, M.
    Pritchard, K. I.
    Lebrun, F.
    Beck, J. T.
    Ito, Y.
    Yardley, D. A.
    Deleu, I.
    Perez, A.
    Bachelot, T. D.
    Vittori, L.
    Mukhopadhyay, P.
    Weber, D.
    Sahmoud, T.
    Hortobagyi, G. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345